Skip to main content
. 2018 Nov 14;9:4777. doi: 10.1038/s41467-018-07250-6

Fig. 1.

Fig. 1

Fabrication and targeted-therapeutic schematics of ND-MMSNs. a Schematic illustration of the preparation of ND-MMSNs. b Schematic shows that inflammation-activatable ND-MMSNs target inflamed glioma sites and phagocytized D-MMSNs would be released to achieve residual tumor theranostics